Form 4: Nephros Inc. Director Joseph Michael Harris Reports Stock Option Grant

Director Joseph Michael Harris reports the acquisition of stock options in Nephros Inc.

Summary

• On May 16, 2024, Joseph Michael Harris, a director of Nephros Inc., filed a Form 4 with the SEC.
• The report details the acquisition of derivative securities, specifically stock options, and the direct ownership of common stock.
• Harris was granted options to purchase 7,323 shares of common stock at an exercise price of $2.14 on May 14, 2024.
• These options vest in three tranches: 2,441 shares on each of 5/14/24, 5/14/25 and 5/14/26.
• Harris directly owns 17,693 shares of Nephros Inc. common stock.
• He also holds options to buy 13,115 shares at $1.25, vesting in installments until 9/6/24, and 7,080 shares at $1.07, vesting until 1/5/25.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock option grants, which is a common practice.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the director.

Industry Context

Stock option grants are a common form of compensation for directors and executives in publicly traded companies, aligning their interests with shareholders by incentivizing them to increase the company's value.

Comparison to Industry Standards

• Stock option grants are a standard component of director compensation packages in similar-sized companies within the medical device and healthcare industries.
• The vesting schedules and exercise prices are generally in line with industry norms for incentivizing long-term performance.

Stakeholder Impact

• The stock option grant could have a slightly positive impact on shareholders as it incentivizes the director to work towards increasing the company's value.

Key Dates